1 July 2021
Cambridge Cognition completes spin-out of Monument Therapeutics
Manchester, UK, July 1st, 2021: Monument Therapeutics, a stratified medicine company, today announced it has raised £2.625 million in seed funding to spin out of Cambridge Cognition Ltd and relocate to Alderley Park, Cheshire. The new company will focus on applying digital...
24 June 2021
Infinity BiologiX and Cytox collaborate to provide new genetic test to predict the risk of cognitive decline due to Alzheimer’s Disease
Powered by Cytox’s genoSCORE, the new test enables physicians to support patients with lifestyle changes, and guide possible use of drug therapy, to delay the onset of disease symptoms … PISCATAWAY, N.J. & OXFORD, England & MANCHESTER, England--(BUSINESS...
17 June 2021
Rinicare to provide continuous vital signs monitoring technology to Indian healthcare system
Manchester-based medtech start-up Rinicare has signed a deal with its distribution partner, Rinicom, to build and deliver an initial 100 units of its continuous vital signs monitoring technology to the Indian healthcare system. Corelink India will be distributing the units...
16 June 2021
Innovate UK funds AssistDent adaption for university dental schools
COVID-19 has placed major strains on dental schools where the practical, patient-orientated elements have faced significant challenges during lockdowns. Recognising the importance and ongoing impact of these issues Innovate UK, the UK’s innovation agency, has awarded...
9 June 2021
Blueberry Therapeutics secures further investment
NPIF – Maven Equity Finance, managed by Maven Capital Partners (“Maven”) and part of the Northern Powerhouse Investment Fund (“NPIF”) has invested £750,000 in Blueberry Therapeutics Limited (“Blueberry”), a drug discovery and...
26 May 2021
Infex Therapeutics partners with Alderley Analytical
Alderley Park, Cheshire Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and ADA analysis of Infex’s RESP-X program. RESP-X is an anti-virulence therapy in-licensed from Japanese pharma company Shionogi. It is designed to help the body...
17 May 2021
INFEX Therapeutics appoints Lonza to manufacture new lung infection drug
Alderley Park, Cheshire - Infex Therapeutics has awarded a £1m contract to Lonza to help progress its RESP-X program, a novel therapy which targets serious recurrent respiratory infections in patients with damaged lung functions. RESP-X is expected to enter clinical trials...
10 May 2021
Digital health start-up Clin-e-cal launches free app to help improve inhaler technique and reduce asthma attacks
Manchester-based digital health start-up Clin-e-cal has launched a free app to help people with respiratory diseases to monitor and improve their inhaler technique. The Clip-Tone Buddy app is the first digital solution which can provide real time feedback and effectively guide a...
4 May 2021
British Pharmaceutical Company Maxwellia Secures Government Future Fund investment to Spearhead Shift in Self-Care
Maxwellia, a pioneering British business that is poised to transform the UK’s self-care market through its specialist model of making more medicines available to buy from UK pharmacies has received a £500k investment from the UK Government via conversion of its...
29 April 2021
Panthera becomes the world’s first clinical trial site to administer Valneva’s inactivated COVID-19 vaccine (VLA2001) to volunteers in phase 3 study
Panthera has today, (28thApril 2021) started vaccinating volunteers in Valneva’s double-blind, phase three, COVID prevention trial. The trial will compare Valneva’s inactivated vaccine, VLA2001, with AstraZeneca’s conditionally approved vaccine Vaxzeria. Unlike...